Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acyl-CoA binding domain containing 4 (ACBD4) is a member of the acyl-coenzyme A binding domain containing protein family. The protein contains a conserved acyl-CoA binding domain which binds medium- and long-chain acyl-CoA esters and may serve as an intracellular carrier of these esters. ACBD4 plays a role in acyl-CoA dependent lipid metabolism, with possible involvement in fatty acid transport and regulatory functions within cellular metabolic pathways. Multiple transcript variants exist, and recent studies link ACBD4 to rare inherited diseases such as retinal dystrophy with leukodystrophy and congenital myopathy 4A, autosomal dominant. While other related acyl-CoA binding proteins have broader functions, ACBD4’s principal annotated roles are in fatty acid metabolism. No direct therapeutic drugs or validated biomarkers currently target ACBD4.
Not applicable, as no known drugs directly target this molecule; general function relates to binding and transport of medium- and long-chain acyl-CoA esters.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acyl-CoA binding domain containing 4 (ACBD4).